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Type two diabetes mellitus (T2DM) is in epidemic proportions world wide (1, 2) 
with obesity being the main driver over the last 30-40 years.  Obesity increases 
the risk of T2DM through an increase in insulin resistance. Establishing the best 
methods of measuring insulin action have occupied researchers for many years, 
indicating that no single method can be universally adopted or be suitable for all 
situations. There are limited data about the effect of bariatric surgery on the 
measurements of insulin resistance. Recently a new test for the assessment of 
insulin resistance, the Dynamic Insulin Sensitivity and Secretion Test (DISST), 
has been developed through the bioengineering department at the University of 
Canterbury as a suitable substitute for the current but complex “gold standard” 
reference method, the euglycaemic hyperinsulinaemic clamp (EIC). The DISST 
method has been validated against the clamp in a range of subjects but not after 
an intervention which is known to fundamentally change glucose homeostasis 
and insulin sensitivity.  The primary aim of this thesis is to test preliminary 
performance of DISST relative to the EIC in a morbidly obese cohort before and 
after bariatric surgery. Secondary aims were assessing the performance of other 
simple fasting tests against the euglycaemic clamp and also assessing weight, 







Insulin and its actions 
 
Insulin is a peptide hormone produced in the beta cells of the pancreas. It was 
discovered in the early 1920s and won its discoverers a Nobel prize for Medicine. 
It had an immediate effect on the lives of those with Type 1 Diabetes who were 
usually children and were insulin deficient. Before the advent of use of insulin, 
Type 1 Diabetes was universally fatal. 
 
Insulin has a number of effects on the body but acts mainly in the hepatocytes, 
myocytes and adipocytes. It stimulates glycogen synthesis and inhibits 
glycogenolysis (3, 4).  Insulin stimulates lipogenesis and lipid storage, while 
inhibiting lipolysis (3).  Insulin also stimulates protein synthesis and inhibits 
protein breakdown. Finally insulin stimulates cell growth and differentiation (3). 
All of these actions are important in energy partitioning and utilisation.  
However, perhaps the most important action of insulin is in glucose uptake and 
utilisation. 
 
Insulin is continuously produced and released by the beta cells of the pancreas to 
maintain background glucose homeostasis. Further release of insulin is mediated 
by the ingestion of food via various neural and hormonal mechanisms to dispose 
of glucose and lipids that have been ingested and absorbed into the body, so 
returning blood glucose concentrations to normal physiological background 
levels after a meal.  
 
The control and release of insulin is determined by many factors including 
plasma glucose, free fatty acids, the autonomic nervous system, fat derived 
hormones and cytokines and gut derived hormones such as Glucagon-like 
Peptide-1 (GLP-1). GLP-1 stimulates insulin secretion, promotes beta cell mitosis 





The actions of insulin are mediated by a cascade of intracellular events which are 
activated after insulin binds to its cell surface receptor.  The scope of these 
intracellular events is beyond this thesis but are well summarised elsewhere (5).  
 
To perform its function, not only must insulin be produced in sufficient quantity 
in response to the appropriate signalling for its release from the beta cells, it 
must also travel via the blood stream, bind to appropriate receptors and the 
signals produced within the cell must respond appropriately. Impairments of any 







Insulin resistance is the inability of insulin to produce a normal physiological 
response to normal physiological concentrations of insulin in the setting of a 
normal physiological stimulus.   Insulin resistance is at times also described in its 
inverse, “insulin sensitivity”. Hence the more insulin resistant a subject is, the 
less insulin sensitive they are, and vice versa. The consequence of insulin 
resistance is an increased secretion of insulin and a higher circulating 
concentration of insulin required to produce the normal response to maintain 
normal glucose and lipid homeostasis (6,7). 
Insulin resistance is an important entity in health and disease. Insulin resistance 
is strongly associated with many other illnesses. These include hyperlipidaemia, 
hypertension, gout, atherosclerosis, polycystic ovary disease and non-alcoholic 
steatohepatitis (8).  
Its most recognised consequence is of the pathophysiological mechanism behind 
T2DM. Insulin resistance leads to hyperinsulinaemia to maintain normal glucose 
homeostasis, but when the beta cells of the pancreas are unable to secrete 
sufficient insulin to maintain normal glucose, T2DM ensues. Some treatments 
currently available for the management of T2DM primarily act to increase the 
insulin sensitivity of cells. Examples of this include Metformin, usually the initial 
treatment in for T2DM (9,10).  Metformin acts by altering signalling within the 
hepatocyte mainly through activation of AMP-activated protein kinase (AMPK) 
(11). Another example is the “Glitizone” group which enhance insulin sensitivity 
by modulating the transcription of the insulin sensitive genes via stimulation of 
the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-
γ) (12). 
The causes of increased insulin resistance may be classified by their relationship 
with the insulin receptor: Either pre, at or post receptor. Some pre-receptor 
causes include antibodies produced against insulin or increased insulin 
degradation. At the receptor level there may be decreased numbers of receptors, 
reduced binding of insulin to its receptor, insulin receptor mutations or insulin 
receptor blocking antibodies. Post receptor there may be ineffective intracellular 
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signal transduction through any of the pathways or mutations in components of 
the signal pathway (for example the GLUT4 transporter protein). Combinations 
of the above are also common.  
Specific conditions or agents can cause insulin resistance. For example, aging 
causes insulin resistance through a decreased production of GLUT4. Increased 
production of insulin antagonists (e.g. Cushing’s syndrome, acromegaly) and 
physiological stress states, such as trauma, surgery, diabetes ketoacidosis, severe 
infection, uraemia and liver cirrhosis are also causes of insulin resistance. 
Medications can also cause increased insulin resistance including 
glucocorticoids, cyclosporine, niacin and protease inhibitors. Anti HIV therapy, 
protease inhibitor associated lipodystrophy and nucleoside analogues have also 
been implicated in the development of insulin resistance (13,14). Insulin therapy 
itself can lead to low titre IgG anti insulin antibodies, though these rarely cause a 
clinically relevant problem.  
Puberty and pregnancy are both normal physiological states that increase insulin 
resistance and is one mechanism for the accelerated growth that occurs at these 





Insulin resistance in obesity  
 
The World Health Organisation states that obesity levels as defined by a BMI 
≥30kg/m² have doubled since 1980. Worldwide 600 million adults (or 13% of 
world population) are classed as obese. With a further 1.9 billion adults (39% of 
population) being overweight (18). This has been a feature of developed 
countries and New Zealand has not been immune from this phenomenon. Data 
from the 2011/2012 New Zealand Health Survey (19) showed that 28% of our 
adult population were obese with a further 35% being overweight. There are 
also particularly important differences between ethnicities in prevalence of 
obesity.  In New Zealand, Maori and pacific island populations have much higher 
rates of obesity than people of European decent, with 44% of adult Maori and 
62% of Pacific peoples reported as obese. 
 
The worldwide epidemic of T2DM has mirrored the rise of obesity (18,19,20). 
This is thought to be mainly mediated through the increased insulin resistance 
caused by obesity. Although most obese subjects are more insulin resistant than 
normal weight subjects there are many obese individuals who have normal 
insulin sensitivity.   
 
The increased insulin resistance in obesity is complex and exact mechanisms are 
still being determined (21,22,23). Obesity leads to a change in a number of 
hormones, cytokines and adipokines that control glucose and lipid metabolism.  
 
Obesity is defined by an increase of adipose tissue. The last 15 years has seen a 
greater understanding of adipose tissue biology.  It is now recognised that it is 
more than simply an organ for lipid storage, but that it also releases a number of 
hormones, adipocytokines and other factors which have an important role in 
energy balance, lipid and glucose metabolism.   
 
One such example is Tumour Necrosis factor alpha (TNF-α). This was first shown 
in 1993 by Hotamisligil et al (24) with increased production of TNF-α in the 
adipose tissue of obese and T2DM mice and that neutralising the TNF-α with 
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blocking antibodies improved their insulin sensitivity. In humans, a direct 
correlation between TNF-α production, obesity and insulin resistance has also 
been shown (25). 
 
In humans TNF-α is not released into the circulation from adipose tissue in any 
significant concentration, but an increase in production of adipose TNF-α acts in 
an autocrine/paracrine mechanism. TNF-α represses genes that would normally 
enhance glucose uptake and increases beta-oxidation (26). These include glucose 
transporter genes (GLUT-4 )(27), the insulin receptor itself and interference in 
the intracellular signalling from the receptor including interfering with 
autophosphorylation and activity and Insulin receptor substrate-1 (IRS-
1)(26,28,29) and counteracts transcription factors that enhance insulin 
sensitivity such as peroxisome proliferated activated receptor gamma (PPAR-
γ)(26,29,30). 
 
TNF- α also upregulates many genes expressed in adipose tissue that are 
responsible for inflammation, immune response and energy balance including 
vascular cell adhesion molecule-1 (VCAM-1), plasminogen activator inhibitor-1 
(PAI-1), IL-6, IL-1beta, angiotensinogen, resistin and leptin (26). 
 
TNF-α also down regulates many genes responsible for Free Fatty acid (FFA) 
uptake and storage and results in enhanced lipolysis and release of FFA and 
cytokines into the circulation (29,31). FFA then inhibits insulin signalling in 
insulin responsive tissues, especially muscle. The released FFA, according to the 
lipid supply hypothesis (Randle hypothesis) (32), act as the predominant 
substrate in the intermediary metabolism. This results in a switch from glucose 
to fatty acid metabolism in skeletal muscle which may explain the decreased 
glucose uptake observed in the insulin resistant obesity state.  
 
Visceral adipose tissue secretes FFA directly into the portal system, thereby 
exerting its effects directly on the liver. In the liver, high concentrations of FFA 
provide abundant substrate for Triglycerides and VLDL-synthesis, and for 
gluconeogenesis.  FFA draining from visceral adipose tissue to the portal 
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circulation and onto the liver decreases hepatic insulin clearance, therefore 
contributing to the hyperinsulinaemia (33). There is also added contribution 
from cytokines and other inflammatory markers such as IL-6. Excess 
triglycerides accumulate in the liver further increasing hepatic insulin resistance.  
 
In muscle high FFA concentrations favour beta oxidation, which diminishes 
glucose uptake (34). Beta-oxidation doesn’t adequately clear FFA from the 
circulation, and even more so in the absence of physical activity (35) so entering 
a vicious circle of on going negative effect on glucose uptake and utilisation. In 
addition excess FFA are stored as triglyceride droplets in muscles, further 
increasing muscle insulin resistance (36,37). 
 
Glycogen synthesis in muscle is also inhibited and as muscle is the main site of 
glucose disposal (80-90%), diminished uptake contributes greatly to 
hyperglycaemia (31,38). In Adipose tissue, FFA inhibits lipoprotein lipase 
activity, which is other wise stimulated by insulin, and thereby reduces clearance 
of FFA from circulation (39) so further exacerbating the problem. 
 
In the Beta cells of the pancreas prolonged exposure to high FFA concentrations 
impairs insulin secretion. This is an additive effect on individuals already 
genetically predisposed to altered insulin sensitivity of beta cell signal molecules 
e.g. protein kinases (40). This is the main mechanism of pre-receptor insulin 
resistance in obesity. 
 
TNF- α has been shown to down regulate the genes for adiponectin.  Adiponectin 
is exclusively produced and excreted by adipocytes and is strongly inversely 
related to insulin resistance in obesity (41). Both insulin and insulin-like growth 
factor (IGF-1) stimulate adiponectin synthesis. Adiponectin improves insulin 
sensitivity by various methods. In the liver it induces fatty acid oxidation, 
decreases lipid synthesis, decreases uptake of FFA and represses 
gluconeogenesis by enzyme down regulation (42,43). In muscle, adiponectin 
favours glucose and FFA oxidation. These effects are partly due to activation of 
9 
 
AMP-kinase (41). Thereby adiponectin decreases plasma FFA and glucose levels 
(42,43).  
 
Adiponectin exerts effects on gene transcription also through inhibition of 
nuclear transcription factor kappaB (44). Additionally adiponectin suppresses 
secretion of TNF-alpha (45) in a typical feedback loop. Obesity is associated with 
reduced adiponectin concentration proportional to the degree of increased fat 
mass. The infusion of Adiponectin has been shown to improve insulin sensitivity 
(46). 
 
Leptin, another hormone produced by adipose tissue and secreted in proportion 
to fat mass, is primarily a signal of energy stores to the hypothalamus where it is 
one of the factors influencing appetite and energy intake.  It also has a direct role 
in insulin sensitivity (47). Leptin deficiency causes an increase in insulin 
resistance. As weight increases leptin levels rise but this may be a relatively 
leptin resistant state as levels get high. The rise in leptin should result in 
CNS/hypothalamic signals to down regulate appetite and to increase metabolic 
use of stored energy. There is somehow a “leptin resistance” so higher levels of 















Measuring Insulin Sensitivity  
There are many ways of measuring insulin sensitivity which suggests that no one 
way is ideal in all conditions. 
There are multiple factors that can influence insulin sensitivity. These include 
production and release of insulin, glucose sensing by the pancreas and the 
response to this, glucose absorption, factors in the liver increasing and 
decreasing gluconeogenesis or glycolysis, peripheral handling of glucose in 
muscle and other organs and tissues, as well as the interplay of other endocrine 
and paracrine hormones such as glucagon, GLP-1, cortisol and growth hormone. 
The current reference method for measuring insulin sensitivity is the 
Euglycaemic Hyperinsulinaemic Clamp (EIC). All other indices of insulin 
resistance are measured against their ability to correlate to the EIC. The EIC was 
first described in 1957 by Andres et al (48) but modified to its current form by 
DeFronzo in 1979 (49). The basic technique is an infusion of high dose of insulin 
given to maintain a high predetermined hyperinsulinaemic concentration. This 
has the effect of shutting down hepatic glucose production and release. At the 
same time a variable rate glucose infusion is given to avoid hypoglycaemia. The 
glucose infusion rate is altered according to frequently sampled blood glucose 
concentrations, measured every few minutes from arterialized blood to maintain 
a steady glucose concentration usually around 5mmol/L.  The principal of the 
high dose insulin infusion is that it shuts down hepatic glucose output so that the 
only source of circulating glucose is from the glucose infusion. By maintaining a 
euglycaemic level below the renal glucose threshold this also eliminates urinary 
glucose losses. An index of insulin sensitivity can then be calculated from the 
average insulin level and the rate of glucose infusion over the last part of the 
clamp, which equals the rate of glucose uptake into cells.  
However the euglyclaemic clamp technique is a complicated test involving 
multiple intravenous cannulae, multiple blood samples and a considerable length 
of time to perform. It is not practical for large studies or population studies but 
remains useful as a research technique. Because it shuts down hepatic 
production of glucose it really is a measure of peripheral insulin resistance. 
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Because of the very high doses of insulin and glucose used the clamp is also not 
being done under physiological conditions. The very high doses of insulin and 
glucose may be causing effects that we are not aware of. Although it is 
considered the reference method, the euglycaemic clamp still has a coefficient of 
variation of around 10% (49). Furthermore, in individuals who have high 
degrees of insulin resistance it cannot be assumed that the standard insulin 
infusion rate is adequate to fully suppress hepatic glucose output, which may 
introduce additional error. In those with morbid obesity there may also be 
marked differences in distribution of the glucose and insulin infusions compared 
to lean subjects.  
Other methods of estimating insulin sensitivity include the intravenous glucose 
tolerance test with minimal modelling which uses a bolus of intravenous glucose 
and then frequent measures of insulin and glucose concentrations.  Glucose 
disposal is modelled using simplified mathematical representations of the 
glucose insulin relationships (50). Using 2 equations, firstly the glucose kinetics 
with assuming single compartment models for glucose distribution, secondly the 
insulin effect. The sensitivity index represents the link between insulin levels in 
the effect compartment and the glucose disappearance from the glucose 
department. Again the difficulty of this test is the time involved (up to 4 hours) 
and the need for multiple blood tests. A major limitation of this method for 
estimating insulin sensitivity in those with established diabetes is the need for 
adequate insulin secretion by the pancreas. The minimal model again largely 
measures peripheral insulin resistance (51). 
The Botnia clamp (52) uses a combination of both the intravenous glucose 
tolerance test and the euglycaemic clamp. This is so an estimate of both insulin 
secretion and insulin sensitivity could be achieved during the one test. The 
intravenous tolerance test gives an estimate of first phase insulin secretion and 
the euglycaemic clamp was begun one hour after the glucose bolus. The M-value 
correlated very well with the standard euglycaemic clamp (r=0.953, p<0.005). 
The same issues with the standard euglycaemic clamp are still present. 
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There have been numerous attempts to derive a simple fasting blood test to 
measure insulin resistance. One off fasting tests include fasting plasma insulin, 
fasting glucose, Homeostasis Model Assessment (HOMA) (53,54,55), 
1/LogHOMA, Quantitative Insulin Sensitivity Check Index (QUICKI)(56), Revised 
QUICKI(57,58), Glucose/insulin ratio, insulin/glucose ratio, Fasting Insulin 
Resistance Index (FIRI)(59), Belfiore GLY (60), Belfiore FFA(60), and McAuley 
Index (61). All of these are very similar in derivation. All have insulin as part of 
their formula and all are products of insulin with glucose and/or triglycerides or 
free fatty acids, or are the inverse or log transformations of these. Multiple small 
validation studies have been conducted to compare these methods of estimating 
insulin sensitivity with the euglycaemic clamp or the minimal model (62). 
The HOMA test has been the most widely used and published of the simple tests. 
HOMA was developed in 1985 (53) and relies on the simultaneous measurement 
of fasting insulin and glucose. The simple formula is: 
HOMA(equation) = (Glucose(mmol/L) x Insulin (pmol/L))/22.5. 
It is easy to calculate and relies on a simple single fasting blood test which makes 
it attractive for epidemiological or large studies where more prolonged and 
complicated measures are impracticable or impossible. The results rely on a 
steady state of insulin and glucose and as it is measured in the fasting state it 
more likely reflects hepatic glucose homeostasis so therefore is more likely to be 
a marker of hepatic insulin resistance. The correlation with clamp studies range 
from r=0.45 to r=0.89 (62) with the best correlation reported by the original 
authors (53). In the original publication the glucose and insulin concentrations 
are taken as the average of three measurements five minutes apart, to account 
for the pulsitility of insulin release.  However, in most studies utilising HOMA 
only one sample is taken, which increases error of the estimate.  The authors 
have modified the equation of HOMA in a more recent publication (54) and now 
have a website for calculating HOMA (55). The two HOMA values however are 
not the same as the HOMA calculator value is calibrated against a young insulin 
sensitive population.  Coefficient of variation is measured at 30% which is mainly 
due to biological variation (53).  
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The second most commonly cited fasting test is QUICKI (Quantitative Insulin 
Sensitivity Check Index) first published in 2000 (56). Further validation tests 
performed in 2005 (63). The basic formula is: 
1 /( (log(fasting insulin µU/mL) + log(fasting glucose mg/dL)) 
To convert to our units of fasting glucose in mmol/L divided by 18. The initial 
study was also performed on a cross section of subjects with 28 nonobese, 13 
obese and 15 type 2 diabetes subjects (56) with a very good correlation with the 
euglycaemic clamp (r=0.78). A further validation study by same group used 116 
subjects ranging from nonobese, obese, type 2 diabetic and hypertensive (63). 
Again correlation was very good (r=0.75). In a recent meta-analysis (62) 
compared to the euglycaemic clamp this has a correlation of r= 0.61. QUICKI has 
also been modified with the addition of a free fatty acid component (revised 
QUICKI). Subsequent analysis (62) shows that this is the best of the fasting tests 
compared to the EIC with r=0.67 but this involved only 7 studies. This however 
compares very favourably with the best OGTT based tests and is within their 
confidence intervals. 
 
Another way of estimating insulin sensitivity is to use a more dynamic test 
integrating glucose disposal and insulin concentrations from an oral rather than 
intravenous glucose load.  Several indices have been derived using a 75g oral 
glucose tolerance test measurements of glucose and insulin from various 
subsequent time points. These include the Matsuda index (64), AUC insulin, 
Stumvoll metabolic clearance rate (65), Stumvoll insulin sensitivity index (65), 
Gutt (66), Belfiore(60) and Cederholm (67). 
A recent meta-analysis (62) of measures of insulin sensitivity versus the 
hyperinsulinaemic-euglycaemic clamp looked at all articles from 1979 (when 
DeFronzo published his Clamp paper) (49) up until 2012 which reported 
bivariate correlations between the euglycaemic clamp and the surrogate 
measure for insulin sensitivity. They performed random effects meta-analysis for 
each surrogate measure to integrate the correlation coefficients of the different 
studies. The pooled correlations (r) were for the fasting surrogate markers 
computer generated HOMA r=0.57, logHOMA-IR r=-0.60 QUICKI r=0.61 and 
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revised QUICKI r=0.68. For the OGTT based tests Stumvoll metabolic clearance 
rate r=0.70, oral glucose insulin sensitivity r=0.70, Matsuda index r=0.67, 
Stumvall insulin sensitivity index 0.67 and the Gutt index r=0.65. In this meta-
analysis there were no studies with mean BMI in the morbidly obese range and 
most studies had average BMI in the mildly overweight. 
Some methods of estimating insulin sensitivity also enable estimates of insulin 
secretion. Again these can be simple EG HOMA-beta%, or complex such as the 
Hyperglycaemic euinsulinaemic clamp also described by DeFronzo et al (49) but 
unable to be performed at the same time. 
Differentiating between the different sites of insulin resistance is also difficult. 
There have been a number of EIC studies done using radioisotope glucose or 
other similar agents to differentiate hepatic versus peripheral insulin resistance. 
These add a further complexity to an already difficult and expensive study.  
In validation studies for various tests most of the individuals included are not 
obese and do not have diabetes. When used in obese subjects or those with 
T2DM the methods all have limitations due to tissue specific effects of increasing 
insulin resistance or altered beta cell function, such that the relationship 
between insulin and glucose cannot be assumed to be the same, and therefore 
the correlation between simple methods and the more complex reference 
methods may not remain as robust.  
The intra-individual variation of insulin is predominantly determined by 
biological variation on a day to day basis. The insulin test and retest variation on 
separate days was 60 % (68), whereas glucose was 15% (68) and triglycerides 
and Free fatty acids were similar (69). The analytical variation made only a 
minor contribution (68). Biological variation will always be present whereas 
analytical variability will lesson over time as better techniques evolve. 
Comparing between different results is also difficult as there are also interlab 
variations up to 3 fold (70).  
Other problems with the simple tests of insulin resistance are the reliance on 
insulin secretion as part of test. If secretion is impaired this will alter results and 
this can be more an issue with dynamic tests. 
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Hyperglycaemia can affect some results of insulin sensitivity. Hyperglycaemia 
above the renal threshold will cause glucose loss in the urine so affecting results. 
Furthermore, hyperglycaemia itself can cause insulin resistance. 
There is also the problem of glucose uptake by non insulin dependent cells or 
organs, for example the brain. 
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Changes in insulin resistance post Roux-en-y gastric bypass 
 
Roux-en-y Gastric bypass (RYGB) remains the most common bariatric surgical 
procedure performed today and is considered the gold standard (71).  
There are two parts to the Roux-en-y gastric bypass. First, a small stomach pouch 
is made by dividing the top of the stomach from the rest of the stomach. Next, the 
first part of the small intestine is divided, and the distal end is brought up and 
connected to the newly formed small stomach pouch. The proximal end of the 
divided small intestine is then attached to the small intestine further down. See 
figure 1 (72). 
 
Figure 1. Roux-en-y gastric bypass (72) 
 
One of the features of RYGB is the resolution of T2DM within days of the 
operation, before any significant weight loss has been achieved (73,74).This is 
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not seen in another common bariatric surgical procedure the gastric band. This 
suggests the operation itself has had an effect on glucose homeostasis. The 
gastric bypass is both a malabsorptive as well as a dietary restrictive procedure 
and it changes the anatomy and physiology of the gut. The gastric band is purely 
a restrictive procedure lessening food intake.  
 
Following Roux-en-y gastric bypass there is rapid improvement within days of 
markers of glucose metabolism and before any substantial weight loss. There are 
2 common theories proposed for the quick improvement in type 2 diabetes 
mellitus. One is the gut hormone theory where the changes in the anatomy and 
the way the food is presented to different parts of the intestine from the stomach 
produce alteration in neural signals and gut hormone release. Commonly 
associated hormones include PYY from the distal intestine which markedly 
increases post prandially after gastric bypass (75) and GLP-1 (76) which also 
markedly increases post prandially after gastric bypass. Both these cause an 
increase in insulin output, and they may also have an effect on the target organs 
for insulin including muscle cells and hepatic cells. There may also be yet 
unknown gut-derived factors that may be being released that are yet to be 
discovered. The operation itself may also interfere with signalling via the vagus 
nerve and its direct control over satiety and appetite from the hypothalamus 
(77). There are falls in both fasting glucose and fasting insulin and changes in 
other hormones associated with glucose metabolism including glucagon, GLP-1, 
free fatty acids and PYY (74). These have a direct effect on the markers of insulin 
resistance that use fasting insulin and glucose to estimate insulin resistance. 
Indices such as HOMA-IR and others based on fasting glucose and insulin and 
lipids all rapidly improve within days of RYGB surgery. This suggests that these 
are predominantly estimates of hepatic resistance as it has been shown that 
hepatic fat rapidly clears post gastric bypass surgery (73,74,78,79,80,81). 
 
A similar picture of rapid improvement in insulin sensitivity without loss of fat 
mass can be found with short term severe caloric restriction with the same 
pattern of lower fasting glucose and lower fasting insulin. The second common 
theory for the quick improvement in diabetes and insulin resistance post 
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bariatric surgery is that of caloric restriction. This has been shown in the use of 
Very Low calorie diets (VLCD) (78,82,83,84,85). Anecdotally I have seen this also 
in the hospital setting where patients with known T2DM are admitted to hospital 
and kept nil by mouth, their blood glucose concentrations improve markedly. By 
dietary restriction and malabsorption there is the decreased absorption of free 
fatty acids and carbohydrate into the portal system.  Therefore the liver is less 
exposed to elements known to increase hepatic insulin resistance. There are also 
less free fatty acids and lipids in the systemic circulation, so less uptake and 
accumulation in the myocytes. This enables lipid stored in hepatocytes and 
myocytes to be cleared relatively quickly, allowing normal switching from lipid 
to glucose oxidation and this improving the insulin sensitivity of these cells. 
There is also clearance of lipids from the pancreatic beta cells which enables 
increased insulin secretion (82). 
 
The actual mechanism is probably a combination of all these as no one individual 
cause is shown to work as well.  
 
Isbell et al (78) compared 9 subjects’ pre and post RYGB with 9 subjects who had 
not undergone surgery but were on the same post procedure diet. They took 
fasting bloods and performed a mixed meal test at baseline and average 4 days 
post procedure. HOMA improved in both groups, insulin response blunted in 
both groups but no change in glucose response. GLP1 response to the meal test 
increased in the RYGB group but stayed same in diet only group. The authors 
concluded that this suggested the improved insulin sensitivity was due to caloric 
restriction. 
 
Euglycaemic hyperinsulinaemic clamp studies do not show this rapid 
improvement in insulin sensitivity. Paradoxically the opposite occurs with using 
the hyperinsulinaemic euglycaemic clamp where this is more of a measure of 
peripheral insulin resistance. Clamp studies done at 2-3 weeks show no change 
in the degree of insulin resistance (86,87), and some studies done at 1 -2 weeks 
post surgery show worsening of insulin resistance, which may be the result of 
surgical stress (88,89). Studies done at 4 weeks to 3 months show variable 
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results (90) where as studies done 6 months or more post surgery show 
improvements in insulin resistance directly correlated to the amount of weight 






The Dynamic insulin sensitivity and secretion test 
 
The Dynamic Insulin sensitivity and secretion test (DISST) was designed to 
mimic the euglycaemic clamp so therefore being a true measure compared to the 
current reference method and more accurate than other markers of insulin 
resistance which use surrogate comparisons.   It was also designed to be much 
simpler and shorter to perform, requiring a small number of blood tests and 
being performed over less than 1 hour. It involves the measurement of glucose, 
insulin and C-peptide at a number of time points with a low dose intravenous 
glucose (10g) infusion and low dose intravenous insulin (1 unit) bolus as 
stimulus for glucose disposal. The DISST test also has the advantage of being 
both a measure of insulin resistance and of insulin secretion. 
 
The DISST test was developed using data from a series of euglycaemic clamps 
originating from a diet and exercise intervention study (92). The clamps were 
performed pre trial and at 16 weeks post trial. The study group consisted of 73 
subjects (so 146 clamps) who were mainly mildly obese. The mean BMI pre 
intervention was 34.4 (SD 4.9) kg/m2 with a range of 24.5-45.2kg/m2 and post 
intervention mean BMI of 33.2 (SD 5.0) kg/m2 and a range of 23.6-44.8 kg/m2. 
These clamp data and pharmacodynamic modelling derived from Bergman (93) 
and others (94,95) was used to form a simulation cohort and the resulting DISST 
model (96). 
 
A number of assumptions are made for the model. These included assuming 
insulin and c-peptide had similar plasma and interstitial volume distribution, 
renal clearance and diffusion constant.  This was assumed as insulin and c-
peptide have a similar molecular weight and similar passive properties. As the 
subjects were fasted the equilibrium glucose was set at 0. With low dose 
injection, saturation by insulin and glucose of available receptors and channels 
was unlikely. Other parameters were identified using a fitting model (97). 
 
Using the above assumptions and the known error in accuracy of assays, timing, 
insulin and glucose dilution errors and an unmodelled suppression of 
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endogenous glucose production, a Monte Carlo analysis (98,99) was performed. 
The metabolic model was then fitted to the stimulated test profiles (glucose, 
insulin, C-Peptide) resulting in an insulin sensitivity index. The clamp fitted 
DISST insulin sensitivity index and the measured clamp ISI correlated very well 
(r=0.93). 
 
The validation study (100) was performed on a group of 123 subjects of which 
50 had DISST, Matsuda index and euglycaemic clamp performed. Of the 50 
subjects having all 3 tests performed 10 were lean (BMI<25 kg/m2), 20 were 
over weight (BMI >25 but <30 kg/m2) and 20 were obese (BMI>30 kg/m2). 
Correlation between the euglycaemic clamp and the DISST was very good at 
r=0.82. This is much better than the other OGTT and fasting measures (62). 
 
However, the DISST test has not been performed on a very obese group of 
subjects or on a group who have had an intervention which fundamentally 
changes glucose metabolism such as bariatric surgery. Therefore the aim of this 
thesis was to examine the performance of the DISST test compared with a 

















All subjects were recruited through Wakefield Obesity Clinic from patients about 
to undergo Roux-en-y gastric bypass with Fobi pouch for weight loss by 
Professor Richard Stubbs. All potential participants were initially approached by 
Prof Stubbs. If patients expressed interest, I then made contact and provided an 
information sheet and then followed up with a telephone call. All subjects were 
obese (BMI greater than 35 kg/m2) and. All participants as part of their 
preoperative assessment underwent an oral glucose tolerance test (OGTT) 
unless they were known to have T2DM. Their glucose status ranged from normal 
glucose control (as per normal OGTT) through to known T2DM.  There were no 
specific additional inclusion or exclusion criteria. The project was discussed by 
myself by telephone with each subject after they had adequate time to review the 
information sheet.  Written informed consent was then obtained.   The study was 





Subjects underwent 3 procedures on 3 separate occasions prior to surgery and 
three to five weeks post surgery. 
 
Prior to the initial test, demographic data were obtained as well as the collection 
of anthropometric and clinical data such as weight, height, waist circumference, 
hip circumference and blood pressure. From these Body Mass Index (BMI), waist 
to hip ratio and body surface area (BSA) were calculated by the Dubois method 
(101).  
 
The tests involved were; Dynamic Insulin Secretion and Sensitivity test (DISST), 
a Euglycaemic Hyperinsulinaemic clamp and a standard meal test. The standard 
meal test was part of another project not included in this thesis but enabled us to 




All subjects continued with their normal diet pre-operatively.   They attended in 
the morning after a 12 hour overnight fast for their investigations. 
Postoperatively all subjects were on low calorie diets of between 600 and 1000 
calories and attended for their investigations after a 12 hour overnight fast. 
Patients with T2DM on medication had individualised plans in regards to their 
medication management.  
 
DISST Study: 
Each subject arrived at the research centre after a 10 hour overnight fast, and 
was instructed not to take any of their regular medications.  An intravenous 
cannula was placed in the arm and blood samples taken for glucose, insulin, C-
peptide, lipids and a full blood count (time zero). Samples were centrifuged 
immediately and aliquot of serum and plasma were frozen for later analysis.  
After the fasting sample was taken, 10g of glucose (20ml 50% glucose) was then 
given intravenously at 5 minutes. At 10 and 15 minutes further bloods were 
taken for glucose, insulin and C-peptide.  Immediately after the 15 minute bloods 
were taken 1 unit of Actrapid insulin was given intravenously. To prevent 
binding of insulin to plastic tubing 10 units of insulin were placed with 0.5ml 
patients own blood and made up to 10ml with normal saline. Then 1mL of this 
solution was then administered. Further bloods were then taken at t25 and t35 
minutes for glucose, insulin and C-peptide. 
 
Euglycaemic Hyperinsulinaemic Clamp Study 
The Euglycaemic hyperinsulinaemic clamps were performed using standard 
technique as per DeFronzo (49). The subject was cannulated in the antecubital 
fossa of one arm and in the dorsum of the other hand. The cannulated hand was 
placed into a heated hand box to arterialise the venous blood (102). The 
temperature of the upper part of the hand box was set at 50 degrees centigrade 
giving an approximate setting of 42-43 degrees around hand. Baseline blood 
samples were taken 10 minutes after hand had been in hand warmer. An 
infusion of insulin of 25% glucose was set up at the antecubital fossa via infusion 
pumps. The established insulin dose for the euglycaemic insulin clamp is 
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40mU/min/m2. The amount to be added to the 50ml syringe is calculated as: BSA 
(m2) x 40 mU/min/m2 x 60min ÷ 15mL (infused volume per hour) x 50 mL 
(syringe volume) = mU of insulin to add to syringe. This can be simplified to BSA 
x 8 = Units of insulin to add to syringe. The insulin infusion was made up from 
Actrapid insulin in units equivalent to 8x BSA added to 3ml of subjects own 
blood, to prevent binding of insulin to plastic tubing(103), and 47 ml Normal 
saline to give total volume of 50ml. This was attached to a Y-non return valve 
extension to the antecubital fossa cannula and initial rate of infusion was 
60ml/hour for 4 minutes, then 30 ml/hr for 3 minutes then a continuous 
infusion at 15 ml/hr after that (so rapidly decreasing hepatic glucose 
production). On the other leg of the Y non-return valve a bag of 1000ml 25% 
glucose was attached. This infusion started at weight in kg as ml/hour (so giving 
an infusion rate of 1mg/kg/min) at 4 minutes (unless blood glucose level was 
elevated above 5. If blood glucose level was above 5 the start of the infusion was 
delayed until blood glucose level was below 5). A blood sample for glucose was 
taken at 0, 4, 7 and 10 minutes then every 5 minutes after that. The blood glucose 
level was used to alter the infusion of 25% glucose with aim to maintain steady 
state of glucose between 4.0 and 5.0 mmol/L. Once stable, further measures of 
insulin were taken from 60 minutes and every 20 minutes for 3 occasions. If 
levels were not stable, the blood specimen for insulin was delayed until stable. 
After the third sample was taken the insulin infusion was stopped but the 
glucose infusion continued for a further 20 minutes to ensure subject did not 
become hypoglycaemic. The subject was then also provided a meal. An index of 
Insulin resistance was then calculated using the standard formula: 
 M  = glucose disposal (consumption) during the steady state time  
  = glucose infusion rate (mg/kg/min) – urinary loses – space correction  
Urinary loses of glucose when euglycaemic are assumed to be stable and 
negligible. The space correction should also be assumed to be zero if steady state 
is reached. 
 
Standard Meal Test 
The Standard meal test was Fortisip® 200ml. Subjects arrived at the research 
centre at 7am after a 10 hour overnight fast. An intravenous cannula was 
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inserted into the arm. Baseline blood samples were taken for glucose, insulin, C-
peptide and incretins. When the test was performed prior to surgery, subjects 
then drank the Fortisip® over less than 1 minute. Postoperatively, subjects were 
asked to drink it over 30 minutes, as the rapid gastric emptying seen post gastric 
bypass surgery precluded them from consuming it quickly as dumping syndrome 
occurs as the meal immediately moves into small intestine. Subjects with normal 
anatomy have meal absorption half-times of about 60 minutes (104). Repeat 
bloods were then taken at 15, 30, 45, 60, 90 and 120 minutes. The baseline 
fasting samples were used in the derivation of fasting indices of insulin 
sensitivity for this thesis.  The remainder of the test is beyond the scope of this 
thesis.  
 
Due to practical time factors, subjects underwent these three tests 
preoperatively simply as they were able to attend.  As there was no reason to 
believe that the effects of one test would influence the outcome of another, this 
was not randomised and was usually in the order DISST, then euglycaemic clamp 
then meal.  There was a minimum washout time of two days between tests. 
 
All subjects then underwent an open Roux-en-y gastric bypass with Fobi pouch. 
The Fobi Pouch gastric bypass has the same type of pouch construction as the 
Roux-en-Y gastric bypass. However rather than staples, it uses a silastic ring 
around distal end of the pouch to simulate the pyloric valve and prevent 
stretching of the opening between the pouch and the section of small bowel. 
 
Post operatively all 3 tests were repeated. The DISST test was always performed 
first at 3 weeks post surgery, followed by the clamp test usually within 2 days 
(but not the following day) of the DISST test (mean, median, range) and finally by 
the meal test. 
 
Subjects were required to be fasting for all investigations and all tests were 
performed between 0730 and 0900 with each subject keeping to specific time. 






All glucose levels were measured on an YSI 2300 Stat Plus, (YSI Life Sciences, 
Yellow Springs, Ohio, USA) which uses the glucose oxidase method. This gives 
accurate glucose results within a minute with a resolution of 0.1mmol/L and a 
precision of +/- 2% or 0.2 mmol/L (which ever is larger) (105). 
 
All blood samples for insulin and C-peptide were immediately centrifuged at 4 
degrees centigrade, and the plasma was then stored at -80 degrees for 
subsequent batch analysis. 
 
Insulin and C-peptide concentrations were all performed at Department of 
Nutrition laboratory, University of Otago, Dunedin. Insulin and C-Peptide were 
both measured by a Cobas electrochemiluminescence immunoassay. Insulin 
levels were reported in both pmol/L and microU/mL. For insulin CV% for lab 
was 3.4%. For C-peptide the %CV for lab was 5.44% 
 
Lipids and full blood count were all processed at the local community laboratory, 
Aotea pathology, Wellington.  
 
For the DISST test, the results were modelled by Dr Paul Docherty, University of 
Canterbury, who was part of the team who have developed the test, using 
computer modelling and an index of insulin resistance (ISI-DISST) and an 
estimation of first phase and second phase insulin secretion was obtained.  
For the euglycaemic clamp test a measure of glucose disposal (M) at steady state 
was obtained from the formula: 
M = glucose infusion rate (mg/kg/min) – urinary loses – space correction. 
With a glucose level below the renal threshold the urinary losses were estimated 
to be zero. With the glucose being at steady state the space correction was also 
estimated to be zero. An index of insulin sensitivity was then obtained using the 
formula: 




For all subjects there were a number of fasting insulin and glucose pairings from 
each of the dynamic tests available (up to three both preoperative and three post 
operative). HOMA (equation) was obtained for each available samples using: 
HOMA(equation) = (Glucose (mmol/L) x Insulin (pmol/L))/22.5 (52). 
The mean of available HOMA(equation) values for each subject pre and 
postoperatively was used as their actual value.  
As the modified and available online calculator will not obtain values with insulin 
above certain values (57.6µU/mL or 400 pmol/L) those that were able to be 
done were calculated and again a mean of the values was obtained to give a 
HOMA(calculator) value (54,55). 
Of the matched pairs where both a HOMA(equation) value and a 
HOMA(calculator) value were available these were analysed to ensure adequate 
correlation between them to assess whether just HOMA(equation) values could 
be used so as not to exclude the most insulin resistant subjects. 
1/logHOMA(equation) was also calculated for each available test. Again the 
mean value was used as actual value. 
QUICKI (56) was calculated using the standard formula: 
 QUICKI = 1/(logInsulin(microU/ml) + logGlucose (mmol/L x 18) 
Again the mean value of available tests for each subject pre and post operative 
was used as actual value. 
 
Statistical Analysis: 
Values were compared for significance by standard student T test of values of 
ISI-clamp, ISI-DISST, HOMA(equation), 1/logHOMA(equation), QUICKI, weight, 
BMI, blood pressure and lipids. Pearson correlation coefficient calculations were 
performed to test correlation of ISI-Clamp with ISI-DISST, HOMA(equation), 
1/logHOMA(equation) and QUICKI as well as  comparing HOMA(equation) with 
HOMA(calculator). Bland-Altman plot analysis was performed on the ISI-DISST 
versus ISI-Clamp. As the ISI-DISST and the ISI-Clamp have different units a 
conversion factor is required. This was converted using the formula: 
ISI DISST= 18000 x Glucose baseline x distribution volume of glucose (0.19 x 




As this was a pilot study to assess usability of the DISST test in a morbid obese 
population and assess its potential use in the early post bariatric surgery setting 
and we were uncertain on how many potential recruits we would be able to 









A total of 11 subjects were recruited for the study with 11 completing 
preoperative and 10 completing postoperative DISST testing, 10 completing 
preoperative euglycaemic clamp and 8 completing postoperative euglycaemic 
clamp and 11 completing preoperative mixed-meal test and 9 completing 
postoperative mixed-meal testing. Baseline characteristics of these subjects are 
shown in Table 1.  Of the 11 participants, nine were female and two male.  Their 
mean age was 51.2yrs (SD 12.1yrs), with a mean preoperative BMI of 48.7 (SD 
9.5).  Of the 11 subjects, 5 had normal glucose tolerance, 2 had impaired glucose 
metabolism, and 4 had T2DM (2 known and 2 diagnosed from preoperative 
OGTT). Only 1 (subject 6) of the T2DM subjects was on any glucose lowering 
medication  (Gliclazide and metformin). This was withheld the evening before 
and the morning of each test preoperatively. The Subjects were on no diabetes 
medication at the time of the postoperative tests.  The mean Blood pressure was 
137.8/78.4 mmHg (SD 21.9/9.9). The mean Total Cholesterol was 5.2 mmol/L 
(SD 0.5), mean triglycerides were 1.8 mmol/L (SD 0.7) and mean HDL was 1.29 

























Table 1: Baseline preoperative individual characteristics of the 11 subjects. 
 














1 59 F 114.2 41.3 Normal  192/ 
100 
5.5 2.8 1.15 
2 63 F 116.5 44.1 IGT 140/ 
74 
5.9 3.4 1.18 
3 49 F 117.4 51.4 Normal  130/ 
70 
5.5 1.1 1.52 
4 48 F 117.5 45.0 Normal  128/ 
76 
5.7 1.5 1.40 
5 24 F 215.6 75.5 Normal  112/ 
66 
   




4.3 1.7 1.86 
7 42 F 143.6 49.8 New 
T2DM 
 5.6 1.7 1.06 




5.1 2.2 1.08 
9 41 F 166.0 53.3 Normal  126/ 
80 
4.6 0.8 1.56 
10 60 M 120.0 44.1 IFG 160/ 
/92 
5.6 1.0 1.27 




4.1 2.0 0.83 
mea
n 
51.2  133.8 48.7  137.8/ 
78.4 
5.2 1.8 1.29 
SD 12.1  29.8 9.5  21.9/ 
9.9 
0.5 0.7 0.24 
 
Abreviations: F=female, M=male, IGT=impaired glucose tolerance, IFG=Impaired fasting glucose, SD=standard 









A computer modeled Insulin Sensitivity Index (ISI-DISST) was calculated on 11 
subjects preoperatively and 10 subjects postoperatively. An example of the 
modeling of subject 1 is given in figure 2.  The mean ISI-DISST   reduced from 
3.07 x10-4L.pmol-1.min-1 (SD 2.18) preoperatively to 2.36 x10-4L.pmol-1.min-1 (SD 








Figure 2.  Sample of DISST analysis for subject one 
 
 
Euglycaemic Clamp results: 
 
The insulin sensitivity index for the euglycaemic clamp (ISI-Clamp) was 
calculated on 10 subjects preoperatively and 8 subjects post operatively. 
Preoperatively Clamp ISI was 2.14 x10-2.mg.L.kg-1.min-1.pmol-1 (SD 1.80) and 
post operatively was 2.00 x10-2.mg.L.kg-1.min-1.pmol-1 (SD 0.76) again this was 
not a significant change (p=0.86). Actual values for DISST ISI and Clamp ISI can 
be seen in table 2. 
 
Correlation between the entire matched ISI-DISST and ISI-Clamp was strong at 
r=0.76 (95% CI 0.45-0.90) (figure 5). Sub analysis of the correlation between ISI-
DISST and ISI-Clamp preoperatively was strong at r=0.81(95% CI 0.37-0.95) 
(figure 3). However the correlation in the post surgical group was weaker r=0.47 
(95% CI 0-0.88) (figure 4). 
 
Bland-Altman plot analysis (Figure 6) shows the bias between the 2 tests, where 
the DISST underestimated the clamp by 0.96x10-2.mg.L.kg-1.min-1.pmol-1 (95% 
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confidence intervals -2.24 to 0.32). Just analysing the pre surgery group (figure 
7), DISST again under estimates the clamp by 1.16x10-2.mg.L.kg-1.pmol-1 (95% 
confidence intervals -2.65 to 0.33) and in the post surgery group (figure 8) DISST 
underestimated the clamp by 0.71x10-2.mg.L.kg-1.pmol-1 (95% confidence 





Table 2. ISI indices pre and postoperative 
 
 Preoperative  Postoperative  
subject ISI-DISST ISI-clamp ISI-DISST ISI-clamp 
1 4.65 5.55 3.35 3.10 
2 2.99 xx 2.25 xx 
3 4.95 4.18 xx xx 
4 4.08 2.57 2.05 2.92 
5 0.94 0.06 1.64 xx 
6 0.69 0.44 1.36 1.86 
7 1.13 0.07 1.05 0.32 
8 1.94 0.82 2.75 1.76 
9 8.35 4.12 2.47 2.43 
10 2.14 2.92 3.09 1.98 
11 1.93 0.70 3.64 1.66 
mean 3.07 2.14 2.36 2.00 
SD 2.18 1.80 0.78 0.76 





















Figure 3. ISI-Clamp versus ISI-DISST preoperative 
 
 
Units: ISI-DISST( x10-4L.pmol-1.min-1), ISI-Clamp (x10-2.mg.L.kg-1.min-1.pmol-1) 
 
Figure 4. ISI-Clamp versus ISI-DISST postoperative  
 
 







Figure 5. Combined ISI-Clamp versus ISI-DSST pre and postoperative 
 
 
Units: ISI-DISST( x10-4L.pmol-1.min-1), ISI-Clamp (x10-2.mg.L.kg-1.min-1.pmol-1) 
 
Figure 6. Bland-Altman plot for ISI-DISST versus ISI-Clamp (Combination of pre 


























Insulin Sensitivity Pre and Post Surgically assessed with Simple Fasting 
Indicies 
 
A HOMA(equation), HOMA(calculator), 1/logHOMA(equation) and QUICKI were 
obtained from the fasting sample data for each dynamic test performed. These 
were averaged to give one estimate of insulin sensitivity preoperatively and one 
postoperatively.  Individual data for HOMA using the standard formula and the 
online HOMA calculator are shown in Table 3.  Summary data for individuals and 
the group as a whole are shown in Table 4.  
 
Table 3: Individual data for the 11 subjects for HOMA(equation) calculated by 
standard formula or HOMA(calculator) by online calculator for fasting data from 





  DISST Clamp Meal Average DISST Clamp Meal Average 
1 pre 2.43 2.62 2.70 2.59 1.26 1.3 1.52 1.36 
1 post 1.93 1.63 1.95 1.84 1.08 0.99 1.07 1.05 
2 pre 5.75 NT 5.40 5.58 2.7 NT 2.62 2.66 
2 post 4.39 NT 3.28 3.84 2.23 NT 1.84 2.04 
3 pre 3.93 2.75 1.96 2.88 1.92 1.48 1.01 1.47 
3 post NT NT NT NT NT NT NT NT 
4 pre 4.02 3.39 4.93 4.11 1.93 1.66 2.19 1.93 
4 post 2.71 3.09 5.61 3.80 1.44 1.62 2.6 1.89 
5 pre 31.21 39.83 NT 35.52 UTC UTC NT UTC 
5 post 13.17 NT NT 13.17 5.71 NT NT 5.71 
6 pre 6.64 10.03 5.02 7.23 1.85 2.79 1.5 2.05 
6 post 5.37 3.91 3.54 4.27 1.96 1.47 1.3 1.58 
7 pre 90.76 72.73 86.31 83.27 UTC UTC UTC UTC 
7 post 17.09 28.87 26.31 24.09 6.94 UTC UTC 6.94 
8 pre 10.55 11.80 24.85 15.73 4.85 5.32 UTC 5.09 
8 post 6.07 3.43 2.69 4.06 3.04 1.94 1.53 2.17 
9 pre 3.95 2.93 4.75 3.88 2.05 1.64 2.34 2.01 
9 post 2.38 1.81 4.63 2.94 1.31 1.03 2.41 1.58 
10 pre 9.43 7.25 6.85 7.84 4.03 3.02 3.09 3.38 
10 post 4.26 3.02 3.33 3.54 2 1.52 1.66 1.73 
11 pre 6.28 5.48 NT 5.88 2.79 2.48 NT 2.64 
11 post 7.52 5.58 6.77 6.62 3.32 2.79 2.95 3.02 







For the available complete data both pre and post operatively combined, 
comparing HOMA(equation) versus HOMA(calculator) the correlation was 
excellent (figure 9) with r= 0.96 (95% CI 0.91-0.99) . If the 3 outlying (most 
insulin resistant) individuals were removed the correlation value was r=0.88 
(95% CI 0.70-0.95). Looking at differences preoperative alone or postoperative 
alone and again with or without the most insulin resistant outliers all gave 
similar results with r values ranging from r= 0.84 to r=0.97. Therefore 
subsequent analysis using HOMA data the HOMA(equation) value was used so as 
not to exclude samples obtained from the most insulin resistant subjects. 
 
 














Table 4. Mean values for HOMA(equation), 1/logHOMA(equation) and QUICKI 
 









(HOMA) QUICKI  
1 2.59 2.42 0.34 1.84 3.79 0.36 
2 5.58 1.34 0.3 3.84 1.71 0.32 
3 2.88 2.18 0.34 ND ND ND 
4 4.11 1.63 0.32 3.8 1.72 0.32 
5 35.52 0.64 0.24 13.17 0.89 0.27 
6 7.23 1.16 0.3 4.27 1.59 0.32 
7 83.27 0.52 0.22 24.09 0.72 0.26 
8 15.73 0.84 0.27 4.06 1.64 0.32 
9 3.88 1.7 0.32 2.94 2.13 0.34 
10 7.84 1.12 0.29 3.54 1.82 0.32 
11 5.88 1.3 0.3 6.62 1.22 0.3 
mean 15.86 1.35 0.29 6.82 1.72 0.31 





Mean values of HOMA(equation) preoperative were 15.86 (SD 23.16) and 
postoperative were 6.82 (SD 6.49) (See Table 4). Although all but one value fell 
there was no statistical difference between preoperative and postoperative 
HOMA(equation) (p=0.14) 
 
HOMA(equation) versus ISI clamp 
 
The correlation of HOMA(equation) versus Clamp ISI preoperative is consistent 
with previously reported studies with r=-0.57 (95% CI 0.0-0.87)(figure 10). 
Postoperative the correlation improves with r= -0.85 (95% CI 0.49-0.97) (figure 
11). When comparing the regression lines between the pre and postoperative 
correlations (figure 12), the slope is shifted to the left postoperatively.  Therefore 
for the same apparent insulin sensitivity by euglycaemic clamp, the HOMA index 
indicates improved insulin sensitivity postoperatively.  This suggests that the 





Figure 10. ISI-Clamp versus HOMA(equation) preoperative 
 
 






Figure 11. ISI-Clamp versus HOMA(equation) postoperative 
 
 











Figure 12. ISI-Clamp versus HOMA(equation) combined 
 
 






1/logHOMA values preoperative were mean 1.35 (SD 0.57) compared with 1.72 
(SD 0.80) postoperatively. Again this difference was not significantly different 
(p=0.13). Using 1/logHOMA preoperative correlation with the ISI-clamp were 
r=0.90 (95% CI 0.67-0.98) (figure 13) and postoperative r= 0.80 (95% CI 0.29-




















Figure 13. ISI-Clamp versus 1/logHOMA(equation) preoperative 
 
 









Figure 14. ISI-Clamp versus 1/logHOMA(equation) postoperative 
 
 






Figure 15. ISI-Clamp versus 1/logHOMA(equation) combined 
 
 








Calculating QUICKI gave a mean preoperative value of 0.29 (SD 0.03) and mean 
postoperative value of 0.31 (SD 0.03). Again this was not statistically different 
(p=0.12). Correlation with the clamp was excellent preoperative with r= 0.82 
(95% CI 0.44-0.95)(figure 16) and was even better postoperative at r= 0.92 
(95% CI 0.70-0.98) (figure 17). However there was a difference in the slope of 
the curves with separation of curves as Clamp ISI increased so again unlikely to 












Figure 16. ISI-Clamp versus QUICKI preoperative 
 
 










Figure 17. ISI-Clamp versus QUICKI postoperative 
 
 








Figure 18. ISI-Clamp versus QUICKI combined 
 
 








The DISST test was able to give estimates of insulin secretion in both first phase 
of insulin secretion and in the second phase of insulin secretion. Although there 
was a trend upwards in the secretion of insulin in the first phase of insulin 
secretion from a mean of 823.5 mU (SD 862.3 mU) to 1091.6 mU (SD 765.8 mU) 
this was not significant with p=0.28 (figure 19). There was no change in the 
second phase of insulin secretion. 2129.4 mU (SD 862.3 mU) to 2217.3mU (SD 
765.8 mU) (p=0.82) (figure 20). There was no correlation between either 
estimated first phase insulin release or second phase insulin release before 












Figure 19. First phase insulin preoperative versus post operative 
 
 









Figure 20. Second phase insulin secretion preoperative versus post operative 
 
 








For the 11 subjects mean initial weight was 133.8kg (SD 29.8, range 114.2-
215.6). If only the 10 subjects with a postoperative weight then mean 135.5kg, 
(SD 30.8, with the same range). For the 10 subjects with post surgery weight 
taken an average of 23 days after surgery mean weight 123.8kg ( SD 28.9, range 
102.9-198.4). BMI in the preoperative group was 48.7 kg/m2 (SD 9.5, range 39.5-
75.5) and in the post operative group was 44.2 kg/m2 (SD 9.3, range 35.5-69.5 
There was no statistical difference between preoperative weight (figure 21) or 
BMI. However if the largest patient was excluded, BMI loss then became 







Table 5.  Weight based changes preoperative versus postoperative 
 
 















1 114.2 41.3 102.9 11.3 37.2 90.1 
2 116.5 44.1 109.4 7.1 41.6 93.9 
3 117.4 51.4 
    4 117.5 45 108.6 8.9 41.6 92.4 
5 215.6 75.5 198.4 17.2 69.5 92 
6 121.2 41.8 109.7 11.5 37.8 90.5 
7 143.6 49.8 130.1 13.5 45.1 90.6 
8 119.6 39.5 107.5 12.1 35.5 89.9 
9 166 53.3 154.8 11.2 49.7 93.3 
10 120 44.1 107.3 12.7 39.4 89.4 
11 120.4 49.5 109.6 10.8 45 91 
Mean 133.8 48.7 123.8 11.6 44.2 91.3 

















Preoperative Total Cholesterol mean was 5.2mmol/L (SD 0.6) and postoperative 
mean was 4.3 mmol/l (SD 0.7). Of the nine subjects with both preoperative and 
postoperative samples the mean fall in Total cholesterol was 0.9mmol/L (SD 
1.15). This just reached statistical significance at p=0.048. Triglycerides 
preoperative mean was 1.82mmol/L (SD 0.77) and postoperative 1.63 mmol/L 
(SD 0.51). Of the nine subjects with both preoperative and postoperative 
samples the mean fall in Triglycerides was 0.4 (SD 0.64). This did not reach 
statistical significance. The preoperative HDL mean was 1.29mmol/L (SD 0.28) 
and postoperative mean was 1.01 mmol/L (SD 0.23). Again of the nine subjects 
with both preoperative and postoperative samples the mean fall in HDL was 




















10 of 11 subjects had Blood pressure (BP) preoperative (subject 7 missing) and 
10 BP were available post surgery (subject 3 missing). Mean systolic BP 
preoperative was 137.8 mmHg, (SD 21.8, range 112-192). Mean systolic BP 
postoperative was 123.8 mmHg , (SD 10.4, range 110-142). The mean fall in BP 
postoperative was 13.3 mmHg (SD 24.1). Mean diastolic BP preoperative was 
78.4 mmHg, (SD 9.9, range 66-100) and mean postoperative diastolic BP was 
76.3 mmHg, (SD 10.5, range 60-94). There was no statistical difference with any 














Two of the modern world’s most common chronic medical conditions are obesity 
and T2DM with a common relationship between the two being the obesity 
related increase in insulin resistance, thought to contribute causally to the 
increasing incidence of T2DM.  
 
For a number of years there has been increasing research interest in establishing 
a easy, repeatable and accurate measure of insulin resistance that correlates well 
with the current reference standard of the hyperinsulinaemic euglycaemic clamp 
as described by DeFronzo (49) in 1979.   
 
Multiple indices derived from fasting insulin and glucose, and some with 
addition of free fatty acids or triglycerides, have only moderate correlation with 
the euglycaemic clamp.  The best of these (revised QUICKI) still only having a 
pooled correlation coefficient of r=0.69 (62).  
 
There are nearly as many indices derived from the dynamic changes in glucose 
and insulin during an OGTT (oral glucose tolerance test), which have slightly 
stronger r values, with the best of these having a pooled correlation coefficient of 
r=0.70 (62).  However these are still within the confidence intervals of most of 
the fasting tests (62).  Therefore we are still in search of a simple method that 
can be utilized in large studies or in clinical practice. 
 
The DISST test was developed to attempt to fill this gap, with a better correlation 
than the simple fasting tests to the hyperinsulinaemic euglycaemic clamp, to 
reflect more the measure of insulin sensitivity of the clamp and be easier to 
administer and cheaper, as well shorter and more palatable to the research 
subject than the OGTT based tests. The whole test is designed to take less than an 
hour with about the same number of blood tests. It is modeled on data derived 
from hyperinsulinaemic euglycaemic clamps. The validation studies described in 




The study reported in this Masters thesis was designed to test the preliminary 
performance of the DISST test in a group of individuals who were more obese 
than those included in the validation studies and therefore may have different 
physiological characteristics determining insulin sensitivity. Furthermore, DISST 
had not previously been assessed after an intervention which is known to 
fundamentally change glucose metabolism such as bariatric surgery.   
 
This study demonstrates a strong correlation between DISST and the 
euglycaemic clamp preoperatively (r = 0.81) and matches nicely with the 
correlation values from the validation studies.   However the relationship was 
not as strong postoperatively (r=0.47).  This would suggest that the factors 
determining insulin sensitivity when measured by the euglycaemic clamp may 
change in a different way than those determining the DISST index. This suggests 
that the DISST test may be more affected by changes in hepatic insulin resistance 
which happen early in the postoperative gastric bypass state which do not affect 
the results of the EIC which mainly reflects peripheral insulin sensitivity. 
 
However, with very small numbers in our study (only 10 preoperative DISST 
versus clamp pairings and only 8 postoperative pairings), we must be very 
cautious in generalizing from this. The confidence intervals for the correlation 
between the preoperative and postoperative ISI-DISST and the ISI-clamp were 
wide and overlapping so we cannot say there is any difference at all. 
 
Bland-Altman plot analysis also showed some underestimation of ISI-DISST 
versus the ISI-Clamp but did cross zero with its wide confidence intervals again 
likely due to the small numbers involved (figure 6). When split into pre surgery 
and post surgery there was still an under estimation with the post surgery group 
performing better but again with even wider confidence intervals (figures 7 and 
8). 
 
With the data available measures for HOMA, 1/logHOMA and QUICKI were able 




As described in the methods chapter, HOMA was calculated using both the 
standard equation (53) to give HOMA(equation) and also using the 
downloadable HOMA calculator (55) to give the HOMA(calculator) value. These 
values were not directly interchangeable as the computer model recalibrated the 
base line to young fit and healthy insulin sensitive subjects. However, because 
the online calculator only accepts insulin concentrations between to a certain 
concentration, in many very insulin resistant subjects HOMA(calculator) was not 
able to calculated for this method. When the two HOMA values were compared 
for available individuals, the correlation was very strong at r>0.95 with narrow 
confidence intervals. For this reason HOMA(equation) was used for further 
evaluation so as to include those who were the most insulin resistant where a 
computer generated HOMA(calculator) could not be obtained. However this 
correlation may not be valid for the very insulin resistant subjects. 
 
The correlation between the euglycaemic clamp and HOMA in the preoperative 
studies was r= -0.57 which is similar to published literature. A recent meta- 
analysis (62) has HOMA(calculator) pooled correlation coefficient as r= -0.57. 
Notably the strength of the relationship increased in the post operative studies 
(r= -0.85) but with the numbers in the study being so small the confidence 
intervals are wide and overlap. 
 
The slope of the regression line for the preoperative and postoperative 
correlations was similar (Figure 12). However, the postoperative comparison 
was shifted to the left, indicating a lower HOMA and therefore better insulin 
sensitivity for the matched comparative clamp ISI estimate. This matches with 
previous data that shows a rapid improvement in HOMA without improvement 
in Clamp ISI (78,106,107,108) in the early postoperative stage.  It also highlights 
the potential differences what each of these methods is measuring in 
fundamental terms.  It may be speculated that because the key physiological 
determinants of fasting glucose and insulin, the parameters used in HOMA, are 
beta cell function and hepatic insulin sensitivity, that RYGB surgery is having its 
predominant effect on these parameters within the first few weeks.  This would 
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be in keeping with the observation that such improvements in glucose 
metabolism occur prior to any loss of fat mass. 
 
Certainly there is data to suggest that differing changes occur. Foo et al (109) 
performed a study where 8 morbidly obese subjects undertook a very low 
calorie diet for 6 days and subsequently had gastric bypass surgery a few weeks 
later. Both had significant falls in HOMA at 6 days after each intervention 
although the post gastric bypass group changes were larger. A short intravenous 
insulin tolerance test was also performed which showed a worsening of glucose 
disposal suggesting worsening of peripheral insulin resistance. Martinussen et al 
(110) using HOMA and an IVGTT showed rapid improvement in HOMA at 1 week 




The other simple methods assessed for estimating insulin resistance from fasting 
blood samples performed even better than HOMA itself. For example, 
1/logHOMA(equation) gave preoperative correlation value of r= 0.90 and 
postoperative value of r=0.80. The recent meta-analysis (62) gave a pooled 
correlation value of r=0.60. QUICKI also performed very well with preoperative 
correlation value of r= 0.82 and postoperative value of r=0.92. The recent meta-
analysis (62) had a pooled correlation value of r=0.61. With these methods, the 
slope of the regression lines differed between pre and postoperative studies. 
This would suggest the possibility that individuals with different degrees of 
insulin sensitivity preoperatively respond to surgery in different ways, and in 
different magnitude, though the same hypothesis that hepatic insulin sensitivity 
is the early determinant still holds true (See figures 15 and 18). Again though 
with the small numbers involved in the study confidence intervals for each of the 
reported correlation figures are large. Unfortunately we were unable to calculate 
revised QUICKI, the best performing fasting test in the recent meta-analysis (62).   
 
Previous studies have shown weak correlation between HOMA, QUICKI and the 
EIC in the early postoperative period. There is rapid improvement in the fasting 
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indices whereas no improvement in clamp is seen until a significant amount of 
weight is lost. In our study there was not a statistically significant weight or BMI 
loss although we would expect these to be clinically significant. Dietary and 
lifestyle studies show improved glucose control from as little as 5% weight loss 
(111,112). The lack of statistical significance is likely due to the small numbers 
involved and also the effect of an outlier, the largest patient, which potentially 
has skewed the data. When this outlier was excluded there was still no 
significant change in weight however the BMI loss was now significant at p=0.02.   
 
It is postulated that one of the reasons that whole body measures of insulin 
sensitivity such as the euglycaemic clamp may not improve immediately 
postoperatively because of ongoing systemic factors related to the surgery. Being 
only 3-4 weeks post operative there may still also be ongoing healing and 
inflammatory markers so influencing effects on insulin resistance. Currently the 
most commonly performed roux-en-y gastric bypass procedures are usually 
done by laparoscopic methods so having fasting healing times. However, the 
operation performed during this study was always an open procedure so having 
larger wounds and slower healing times. Certainly at least a couple of subjects 
had delay in healing of their abdominal wounds which has the potential to affect 
results with increased inflammatory markers having a direct effect on insulin 
resistance.   
 
If we ignore the effect of insulin resistance and focus on glucose outcomes per se 
there are marked improvements in diabetes control with glucose levels falling 
throughout. This is seen in both fasting glucose levels and also peak glucose 
levels seen in meal study and DISST tests (data not presented). Multiple studies 
have shown that type 2 diabetes mellitus can rapidly improve following gastric 
bypass surgery (before any appreciable change in ISI-clamp) (73,74). 
 
There are multiple mechanisms involved for this improvement. These include 





Calorie restriction is an important component of the gastric bypass operation as 
with the small stomach pouch subjects cannot eat large amount. With the small 
stomach pouch the subject postoperatively cannot have a large meal as there is 
no room for it in the stomach. Large meals also lead to the dumping phenomenon 
where there is rapid transit of meal from the stomach to the small intestine. This 
is more common with higher carbohydrate meals. Common symptoms include 
abdominal pains, nausea and vomiting, flushing, dizziness, lightheadedness and 
palpitations and most subjects find it particularly unpleasant (113). There are a 
number of studies that do show rapid improvement in glucose control just by 
restricting food intake (109,110,114). These show rapid improvement in the 
fasting measures of insulin resistance such as HOMA and can be equal to that of 
gastric bypass.  
 
Other mechanisms include a change in gut hormone release with changes 
occurring almost immediately in important appetite regulating hormones such 
as GLP-1, PYY and Ghrelin (76,107,108,115) so not having the desire or need to 
eat. These do not occur in very low calorie diets suggesting that it is the 
operation and the change in anatomy that causes this alteration.  
 
The DISST test also models insulin secretion. Results suggest possible improved 
first phase insulin secretion although this does not reach statistical significance 
with our small numbers. Multiple studies largely using oral glucose tests show an 
early and exaggerated rise in insulin secretion post gastric bypass. There is then 
a fall of insulin so the area under curve for total secretion remains the same 
(107). The reasons for this could be multi factorial but the two likely causes are 
firstly decreased fat/lipid accumulation in the pancreas allowing beta cells to 
perform better and secrete more insulin (82,110). The second possibility is the 
effect of the operation itself. There is a marked increase in Glucagon-like peptide 
1 (GLP-1) secretion in the post prandial setting (76,116) which directly increases 
insulin production, as well as affecting the vagal impact so both increasing 
pancreatic output (110,117,118). This also has effects on central mediated 
satiety so decreased oral intake (118). Increased concentration of postprandial 
Peptide YY3-36 in the gastric bypass subject also has alters vagal stimulation (75). 
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A third possibility could be the decreased calorie load required from having only 
a small stomach remnant and so the pancreas does not have to produce as much 
insulin. This same phenomenon is seen in those on very low calorie diets 
(82,110). Certainly this increased first phase insulin release has been 
demonstrated elsewhere (110) following gastric bypass surgery.  
 
Interestingly there is little change in the measured second phase insulin 
secretion. There is limited data to show change in this second phase secretion. 
Available data suggests a decrease in this second phase over the first few months 
(106,119). This may be because of the exaggerated first phase reaction so down 
regulation of the second phase.  
 
There is also sustained control of T2DM in the medium term of 1-2 years 
(120,121,122) post gastric bypass surgery. This is likely to be a combination of 
the early initial changes in hepatic insulin sensitivity and gut hormone release 
and then the addition of increased peripheral insulin sensitivity as the subjects 
weight falls. The peripheral insulin sensitivity as measured by the clamp 
improves in direct correlation to the weight lost (86,87,91). Sustained weight 
loss by lifestyle measures can also markedly improve glucose metabolism. This is 
seen in two major diabetes prevention studies, the Finnish Prevention Study 
(111) and the Diabetes Prevention Program (112) with prevention of T2DM of 
between 43 - 58% on as little as 5% weight loss, much less than the weight loss 
achieved usually by gastric bypass surgery. 
 
Changes in lipid profile were less predictable. There was a significant 
improvement in total cholesterol but also a significant drop in HDL cholesterol. 
Surprisingly there was no change seen in Triglyceride concentrations. In the 
Buchwald meta-analysis hyperlipidaemia improved in 70% (121) but again this 
was over a longer follow up period. Only one subject in our study was on lipid 
lowering medication which was stopped at the time of surgery and remained off 




There were no changes seen in blood pressure in the current study. However the 
effect of medication confounds this analysis. Five of the subjects were on blood 
pressure medication prior to surgery and all remained off the medication at the 
time of postoperative assessment. This same issue is also described by Schauer 
et al (122). The first major metaanalysis (121) of effects of bariatric surgery 
showed that 78.5% of subjects had improved blood pressure. This though was 
over prolonged follow up and not in the immediate postoperative phase. 
 
 
Limitations of the research: 
There were a number of limitations to this research. These can be simplified into 
recruitment, technical and analytical issues. 
 
The major limiting factor of this study was of course the small numbers of 
participants.  The total number of participants was limited by the number of 
consenting subjects who underwent surgery during the time available for this 
Masters. Recruitment was not as good as was hoped with a total of only eleven 
subjects recruited. Based on previous throughput it was expected that we would 
have enrolled twenty five subjects in the same timeframe. A number of factors 
limited the ability to recruit more. All subjects for practical reasons had to be 
from the greater Wellington region as they were asked to come into the research 
centre on six occasions (three pre surgery visits and three post surgery visits). 
Even with this limitation two of the research subjects were based in the Kapiti 
Coast with round trips of almost 100km and both very happy to do this. As 
greater than 50% of the patients undergoing surgery were from other regions 
(Canterbury, Hawkes Bay and Manawatu being the bulk of these) this 
immediately restricted the number of potential subjects. Of those who met the 
geographical criteria there were still a number of factors that limited ability to 
take part in the study. Some understandably were just not interested in taking 
part in the study, others had work commitments that they could not get around, 
and others had not enough time to be able to do the pre surgery studies given 
their surgery scheduling. Furthermore there was a significant reduction in the 
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numbers of people coming forward for privately funded surgery over the time of 
this study due to the world financial crisis.  
 
This lack of numbers means making any strong conclusions in regards to the use 
of DISST in the morbidly obese or in a postoperative bariatric surgery population 
impossible to make. 
 
Technical issues with each of the individual tests were common. For the 
Euglycaemic hyperinsulinaemic clamp a number of difficulties were 
encountered. Cannulation of obese individuals can be very difficult. All subjects 
required 2 intravenous cannulae; one in the dorsum of the hand and another 
placed in the antecubital fossa. The antecubital fossa cannula was for the infusion 
of the glucose and insulin solutions and no problems were encountered during 
any of clamps once was in place. The cannula in the dorsum of the hand though 
was used for obtaining blood specimens for glucose assessment every 5 minutes 
and on a number of occasions this failed usually only once though often in the 
middle of the clamp study. This required a rapid recannulation knowing that you 
continued to need regular blood samples.  
The protocol used for the clamp worked very well for the majority of the 
patients. The two exceptions were the two patients with marked insulin 
resistance. Both required almost no glucose infusion (1 and 3 ml/hour of 25% 
glucose whereas the protocol started them both of at about 100 ml/hr). This 
prolonged the clamp study significantly before steady state was reached. 
 
Analysis issues include the suitability of the euglycaemic clamp in the obese and 
the very insulin resistant subjects. In obesity the dispersion of both insulin and 
glucose differs from lean subjects and this requires differing rates of infusion. 
For the very insulin resistant subjects it is debated whether the infused insulin 
doses may not be sufficient to switch off all hepatic glucose output, thus create a 






The DISST test was technically straight forward. The two main issues were again 
IV cannulation, though only one was required with only one failure during all 
DISST tests performed. The most challenging aspect of test was to give each 
subject one unit of insulin intravenously. This is such a small dose that 10 units 
were mixed with some solution of patients blood and Normal saline made up to 
10 ml and 1 ml infused. The results suggested that this was effective with a clear 
increase in the insulin concentration measured at the first post bolus blood 
sample. 
 
With the meal test the main issue was with nausea and vomiting in the 
postoperative test. This is likely to be a combination of volume (200ml into a 
small remnant stomach pouch) and dumping as gastric emptying would still be 
faster than what would be a normal rate of about 60 minutes. Subject one drank 
their meal over 10 minutes and had severe nausea coming on at about 30 
minutes and vomited twice at 50 and 60 minutes. All other subjects subsequently 
had their meal test drink over 30 minutes. There was no further vomiting but all 
had marked nausea between 40 and 60 minutes. There was not funding to 
further explore some of these factors although samples continue to be stored for 
future use. 
 
There were a number of analytical issues. With the hyperinsulinaemic clamp the 
last part of the clamp was used to determine insulin sensitivity once steady state 
was achieved. However in the two most insulin resistant subjects both were very 
slow to reach steady state so potentially introducing more variability. 
 
As discussed above,  the computer generated HOMA insulin values could not be 
derived at all in two subjects and in the preoperative value for a further one 
subject. This excluded results from our most insulin resistant pair and one of the 
results from a third. This may have had adverse effects on using HOMA as a 
comparator to the clamp. 
 
All fasting measures were done on single point insulin and glucose measures. 
The release of insulin is pulsatile so ideally 3 samples over 10minutes would give 
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better mean basal concentrations. This was somewhat mitigated by having a 
number of differing tests on different days but due to chance each of these may 
have been done at a peak or a trough of an insulin pulse so affecting overall 
average (53). 
The fasting tests are also measures of basal insulin resistance whereas any 
dynamic test (Clamp, DISST, OGTT based) is more a measure of stimulated 
insulin resistance. 
 
There was also some missing data as not all tests were able to be completed in all 
subjects.   
 
There were also a number of strengths to this study. The DISST test was easy to 
perform and well tolerated.  There was no problems reported with the glucose 
infusion in comparison to the OGTT which can be poorly tolerated both with the 
difficulty drinking 300ml of a very sweet drink and some nausea that can occur. 
There were also no problems associated with the insulin bolus. Being only 1 unit 
makes hypoglycaemia very unlikely and given that the dose is intravenous any 
issue would occur within the time of the test. With a simple and easy to follow 
protocol the DISST test was quick with the whole test taking about 40-45 
minutes including preparation time. The ISI-DISST also at least in the 







This study was designed to compare the performance of the newly developed 
DISST method for measuring insulin sensitivity with other methods in a group of 
morbidly obese individuals before and after bariatric surgery.  Overall the DISST 
test strongly correlated with the reference method, the euglycaemic clamp in the 
preoperative tests.   DISST had a stronger correlation with the clamp than did 
HOMA, the most commonly used simple surrogate measure of insulin resistance. 
Notably in this study both 1/logHOMA and QUICKI also had very strong 
correlation with the clamp.  However as the study numbers were small the 
confidence intervals were all wide and overlapped.  
 
After surgery, when it is known that there are major changes in glucose 
homeostasis, DISST had a much weaker correlation with the clamp. The nature of 
the relationship between the different measurements postoperatively was also 
altered, suggesting that the fundamental physiological determinants of insulin 
sensitivity being measured by each change in different ways with RYGB surgery. 
Gaining a better understanding of this with further studies in larger numbers 
may help to tease out the mechanistic causes of insulin resistance associated 
with obesity.  For example euglycaemic clamp studies with glucose tracers 
enabling better compartmentalization of the glucose kinetics with respect to 
liver output and whole body uptake would be extremely valuable.  However this 
study has demonstrated that the DISST method is a method which can be used to 
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Comparison of DIST versus euglycaemic hyperinsulinaemic clamp 
before and after Roux-en-Y Gastric Bypass for the measurement of 
insulin resistance 
 
Principal investigator: Professor Richard Stubbs, Director, Wakefield Biomedical 
Research Unit, Wakefield Clinic, Wakefield Hospital, Wellington 
Co-investigators: Dr John Wilson, Wakefield Clinic, Wakefield Hospital, 
Wellington, Dr Mark Hayes, Wakefield Biomedical Research Unit, Wakefield Clinic, 
Wakefield Hospital, Wellington, Dr Jeremy Krebs, Clinical Leader Diabetes and 





You are invited to take part in a study assessing the methods of measuring insulin 
resistance in a group of subjects before gastric bypass surgery and after gastric bypass 
surgery. Please take as long as you need to consider whether or not you wish to take 
part. You have the right not to take part. 
 
Participation: 
Your participation is entirely voluntary (your choice).  You do not have to take part in 
this study, and if you choose not to take part you will receive the standard 
treatment/care available. This will not affect any future care or treatment. 
If you do agree to take part in the study, you are free to withdraw from the study at 
any time, without having to give a reason, and this will in no way affect your future or 
continuing health care. 
Participation in this study will be stopped should any harmful effects appear or if the 
doctor feels it is not in your best interests to continue. 
 
About the study 
The main aims of the study are to analyse the use of a new test (DIST) that measures 
insulin resistance and compare that test with the current gold standard for insulin 
resistance (Euglycaemic hyperinsinsulinaemic clamp) in a group of people before 
gastric bypass and after gastric bypass. As part of this study we would also wish to 
analyse gut hormone response and insulin response to a mixed meal (combination of 
carbohydrate, fat, and protein) before and after surgery, to see how this relates to 
insulin resistance.  
Subjects for the study will be selected from those about to undergo gastric bypass 
surgery at Wakefield Hospital. The investigators involved in the study will be 
involved in the selection. 
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We aim to assess at least 24 subjects. 
The study will be run at Wakefield Hospital and all investigations will be performed 
in the clinical investigation room within the Wakefield Clinic. 
The recruiting period will be over a 12-month period. The initial investigations will be 
done at 1-2 weeks prior to bypass surgery and 2-4 weeks after surgery and 6-12 
months after surgery. 
  
What will happen during the study?  
You will be asked for written consent for the study. We will go through the 
information sheet and any outstanding questions will be answered. You will then sign 
a consent form agreeing to your willing participation. You will then be asked about 
some demographic details as well as medical and family history and medication use. 
You will have your weight taken as well as your height as these are needed for certain 
calculations for investigations. These will be updated on the visits after surgery. 
During the pre bypass study week you will be asked to come into the research facility 
on 3 separate days having fasted overnight. 
On one of these days you will have a test called a euglycaemic hyperinsulinaemic 
clamp. This is the current best test we have for measuring insulin resistance. This test 
involves the insertion of 2 intravenous lines in one arm, usually one in the elbow 
region and one in the hand. One of these lines is for the infusion of insulin and 
glucose at a set rate. The second line will be to take blood samples from. This hand 
will be placed in a warming box to increase the blood flow. A small blood sample will 
be taken every 5 minutes from the line to ensure your glucose levels remain constant. 
The test itself will take up to 2.5 hours but with setup and post test observation the 
time involved will be about 4 hours in total.  
The second test (DIST) involves putting another intravenous line in. A blood sample 
is then taken just prior to the commencement of the test. At the beginning of the test 
you are given an intravenous dose of glucose (10g). Blood samples are then done at 5 
minutes and 10 minutes through the line. After the 10-minute blood sample you are 
given a dose of intravenous insulin (1unit fast acting insulin) and further blood 
samples are taken at 20,25 and 35 minutes. The test is then completed but you are 
observed for a further half hour. The total time with us should be approximately 1.5 
hours.  
The third test involves a mixed meal test where you are given a set volume of a liquid 
food containing a known amount of calories made up of carbohydrate, fat and protein.  
 
You will have an intravenous cannula placed to enable simpler blood sampling to take 
place. You will have some blood samples done at baseline (before the mixed meal) 
then further samples at 15, 30, 45, 60, 90 and 120 minutes The total time with us 
should be about 3 hours.  
The above tests will then be repeated at 2-4 weeks after your gastric bypass and again 
between 6-12 months after gastric bypass. 
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Benefits, risks and safety 
 
The benefits of the study 
There will be no direct benefits to you for participating in the study. The study is 
being performed to establish easier and perhaps better ways of assessing insulin 
resistance, which is a key factor in the problems associated with severe obesity. Such 
assessments are likely to contribute importantly in the future to the development of 
better treatments for obesity and its related problems.  
The study is a non-therapeutic study. This means we will not be giving you any 
medication or other treatment that will give you any tangible benefit. The data we 
gain may however be useful in deciding in the future who may benefit most from 
gastric bypass surgery. 
 
The risks and/or inconveniences of the study 
The inconveniences of the study include the time involved. Each clamp study will 
involve a time commitment of 4 hours in the morning (3 separate times) and each 
DIST test will involve 1.5 hours in the mornings (3 separate occasions). The Mixed 
meal test will take about 3 hours in the morning. (3 separate occasions). IV line sites 
have risks of bruising, inflammation and infection although this in minimized by 
removal of lines at completion of the observation period after testing. The lines 
occasionally stop working during the testing process so additional lines may be 
necessary during the test.  
During the test and at the completion of the test the other main side effect will be 
hypoglycaemia (low blood sugar). During the clamp study you will have blood sugars 
measured at 5-minute intervals to insure this does not happen. After both tests are 
completed there is an observation period mainly to ensure that you do not become 
hypoglycaemic following the procedure. For the clamp study the main risk of 
hypoglycaemia is during the study and we expect about 5% of subjects will become 
hypoglycaemic during the study. This will be treated immediately with glucose and 
altering of insulin infusion. We expect the episodes of hypoglycaemia to be only 
minor in the majority. For the DIST test we are not expecting any abnormalities with 
hypoglycaemia as the insulin dose is so small but we will be observing for this as a 
safety measure. 
Occasionally people feel nauseous with glucose or insulin infusions and with a mixed 
meal test. The mixed meal test also has a taste that some people find unpleasant. 
 
 
Inclusion and exclusion criteria 
Inclusion criteria  







Exclusion criteria  
Age under 18 years 
Individuals with poor venous access 
Significant known cardiac / renal  impairment which may increase any risk 
arising from hypoglycaemia. 
  
Costs, Payments and Reimbursements 
There will be no additional costs for taking part in the study and no payments 
required. There will be no reimbursements of costs. Parking is available at Wakefield 
Hospital at no cost. 
 
What happens if there are any ill effects from the trial?  What compensation will be 
available? 
We do not expect any major side effects from the trial. Any untoward event will be 
treated as medically appropriate. Each test will be done under the direct supervision of 
a trained medical professional.  
In the unlikely event of a physical injury as a result of your participation in this study, 
you may be covered by ACC under the Injury Prevention and Compensation ACT. 
ACC cover is not automatic and your case will need to be assessed by ACC according 
to provisions of the 2002 Injury Prevention and Compensation ACT. If your claim is 
accepted by ACC, you still might not get any compensation. This depends on a 
number of factors such as whether you are an earner or non-earner. ACC usually 
provides only partial reimbursement of costs and expenses and there may be no cover 
for mental injury unless it is a result of physical injury. If you have ACC cover, 






Will my GP be told I am in the study? 
Your GP will be informed you are participating in this study unless you specifically 
wish this not to be done. 
What will happen at the end of the study? 
At the end of the study all data will be collated together with others who have been 
involved in the study and the data will be analysed. There will be no direct follow up 
of the tests that you have performed but you will continue to be followed through the 
usual way following your bypass surgery. 
Where can I get more information about the study? 




If I need an interpreter, can one be provided? 
A qualified interpreter will be available if required. 
Additional support 
You may have a friend, family or whānau support to help you understand the risks 
and/or benefits of this study and any other explanation you may require. 
If you have any queries or concerns regarding your rights as a participant in this 
study, you may wish to contact an independent health and disability advocate: 
Free phone: 0800 555 050 





No material that could personally identify you will be used in any reports on this 
study. 
 
Each subject will be assigned a unique code and this will be used to identify subjects 
with specimen results. Some of the investigations performed however will be part of 
the current surgical workup and will as such be identifiable to others. 
 
Records of the personal details and other history and examination findings as well as 
results of investigations will be kept in a secure and confidential manner. This data 





The data collected will be analysed in a scientific manner using appropriate statistical 
methods. The aim is publication of the results in appropriate scientific journals and 
presentation of findings at appropriate medical meetings. There is always a delay 
following data collection and subsequent analysis and presentation of findings. A 
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Comparison of DIST versus euglycaemic hyperinsulinaemic clamp 
before and after Roux-en-Y Gastric Bypass for the measurement of 
insulin resistance 
 
Principal investigator: Professor Richard Stubbs, Director, Wakefield Biomedical 
Research Unit, Wakefield Clinic, Wakefield Hospital, Wellington 
Co-investigators: Dr John Wilson, Wakefield Clinic, Wakefield Hospital, 
Wellington, Dr Mark Hayes, Wakefield Biomedical Research Unit, Wakefield Clinic, 
Wakefield Hospital, Wellington, Dr Jeremy Krebs, Clinical Leader Diabetes and 
Endocrinology, Wellington Hospital, Wellington 
 
Insulin Resistance is a marker for metabolic disease and predicts the development of 
type 2 diabetes and cardiovascular disease (1). The current gold standard for testing 
whole body insulin sensitivity is the euglycaemic hyperinsulinaemic clamp technique 
(2). However this is a time consuming and intensive investigation for both 
investigator and subject. An alternative is the intravenous glucose tolerance test with 
minimal modelling as developed by Bergman (2,3,4). However this is also invasive, 
time consuming and expensive. Other surrogate measures for insulin resistance based 
on fasting blood samples of insulin and glucose (5), the most commonly used being 
HOMA (6), or indices using the oral glucose tolerance test (Matsuda index) (7) have 
been developed. Although much simpler, less invasive and less expensive, these 
measures have variable correlation with the euglycaemic hyperinsulinaemic clamp, 
particularly in individuals with established diabetes. 
 
A new technique called the DIST (Dynamic Insulin Sensitivity Test) has been 
developed and validated against the euglycaemic hyperinsulinaemic clamp in subjects  
of various weights and non-diabetic and diabetic (r=0.97, n=60).(8) Recent further 
validation has been performed on a different population group. (r=0.98, n=146, 
unpublished). 
 
Additionally, because DIST does not require supra-physiological levels of insulin, it 
may offer a more appropriate measure of insulin sensitivity than a clamp study. DIST 
is less time consuming and less expensive and therefore appears well suited for the 




In the obese there is an increased preponderance of metabolic syndrome and diabetes. 
This is thought to be related to a reduction in insulin sensitivity with increased fat 





Conducting euglycaemic hyperinsulinaemic clamps is more difficult in obese and 
super-obese subjects, mainly through the technical aspects of venous access. A 
simpler method of assessing insulin resistance would make subsequent investigation 
of this group of subjects simpler and easier both for the subjects and for the 
investigators. 
 
Although DIST has been validated in obese subjects, it has not been assessed before 
and after an intervention known to alter insulin sensitivity. Gastric bypass surgery is 
known to profoundly improve insulin sensitivity. Therefore it offers an ideal model to 
assess how DIST performs in this setting. The mechanism for improved insulin 
sensitivity following gastric bypass surgery remains unclear, but one hypothesis is 
that there are changes in the entero-insular axis. Known putative hormones include 
GLP-1, GIP, PYY and Ghrelin. 
 
In this study we plan to assess the new DIST technique in comparison with the 
euglycaemic hyperinsulinaemic clamp technique in the obese and super obese both 
pre op Roux-en-y gastric bypass, within 2-4 weeks post gastric bypass and at 6-12 
months post gastric bypass.  
 
As part of this project we will also assess changes in gut hormones and insulin in 







We will recruit 24 participants for this study. The subjects will be privately funding 
their gastric bypass through Prof Richard Stubbs at Wakefield Clinic. They will 
undergo the usual bypass surgery assessments. Prof Stubbs, or other investigators will 
approach the subjects, regarding their potential participation in the study. Their 
participation will be entirely voluntary and declining participation will have no effect 
on any subsequent surgery or other treatment.  
 
Written consent will be obtained from all participants. 
 
The study will consist of 3 separate tests over 3 separate days in the same week at 3 




The 3 tests will be: 
-euglycaemic hyperinsulaemic clamp 
-DIST 
-Mixed meal test 
 
The euglycaemic hyperinsulinaemic clamp 
 
The euglycaemic clamp consists of the participant arriving at 8am having fasted 
overnight.  A retrograde cannula is inserted in the dorsum of hand or wrist and 
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connected to a saline primed microbore 30cm extension tubing and a three way tap. 
The hand is placed in a box heated to 60ºC to allow maximal vasodilation to 
“arterialise” the venous blood.  This line is used for sampling.  A second cannula is 
inserted in the antecubital fossa of the same arm and is connected, via a dual adapter 
with a non-return valve, to insulin and glucose infusions.    
 
Body Surface Area (BSA) is calculated from measured height and weight using the 
DuBois and DuBois formula. 
 
Baseline insulin and glucose values are measured.   
 
Insulin infusion is set up after the patient has been cannulated. 47 mL of saline and 3 
mL of the participant’s blood are mixed in a 50 mL syringe. The blood is needed to 
reduce insulin binding to the infusion tubing. The established insulin dose for 
euglycaemic hyperinsulinaemic clamp is 40mU/min/m
2
.  The amount to be added to 
the 50ml syringe is calculated (BSA (m
2
) x 40 mU/min/m
2
 x 60min ÷ 15mL (infused 
volume per hour) x 50 mL (syringe volume) = mU of insulin to add to syringe). This 
can be simplified to BSA x 8 = Units of insulin to add to syringe.  
 
The clamp then commences with a loading dose of insulin of 60mL/hr for 4 minutes, 
then 30mL/hr for 3 minutes then 15mL/hr as the ongoing infusion rate for the rest of 
the test.  This rapid loading of insulin allows for rapid declines in hepatic glucose 
production over the first approximately 20minutes of the procedure. 
 
The glucose infusion (Glucose solution 25% = 250mg/ml) is started 4 minutes after 
the insulin.  However if the glucose value is above 5.5mmol/L at baseline the glucose 
infusion is started once the glucose level is 4.5mmol/L.   
 
Dose of glucose infusion is calculated by Weight x 60 min ÷ 250 mg/ml (G25% 
solution) = ml/hr (Simplified Weight x 0.24). This delivers 1mg/kg/min. Start rate of 
glucose is the same as weight (kg) in ml/hr, which is just above 4 mg/kg/min. The 
glucose rate is then adjusted over the remainder of the test to maintain euglycaemia. 
 
The set point of the test is 4.5mmol/L of glucose unless the baseline value is between 
4-5mmol/L.  Then the baseline value is the set value. Steady state is deemed to be 
when Glucose level and Glucose infusion rate are stable ± 10%. 
 
At 60 minutes, 80 minutes, 100 minutes and 120 minutes Insulin levels are measured. 
 
The data is then analysed using standard formula to obtain an insulin sensitivity index. 
 
The participant will need about 4 hours of time for the test. During the test the 




The DIST technique requires participants to arrive fasted at 0800. They then have a 
baseline insulin/c-peptide /glucose measured. They then have an iv glucose injection 
(10g). A repeat insulin/c-peptide/glucose is done at +5 and +10 minutes. An insulin 
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dose (1 unit) is given at (+10 minute) and repeat insulin/glucose/C-peptide performed 
at +20 minutes and +30minutes.   
 
These results are then used to give an insulin sensitivity index using a standard 
formula. The results will then be compared via statistical analysis to verify whether 
the technique is satisfactory for use as investigative procedure in Gastric bypass 
population.  
 
Mixed meal test  
 
A mixed meal test using a liquid meal of known volume, calories, fat, carbohydrate 
and protein to assess insulin, GLP-1 and GIP profiles before and after surgery. The 
participant will arrive fasted at 0800. Baseline blood samples of glucose, insulin, 
GLP-1 and GIP will be measured. The participant will then drink the mixed meal 
(Ensure plus). Repeat Glucose, insulin, GLP-1and GIP will be done at 15, 30, 45, 60, 
90, and 120 minutes.  
 
These will be done in the same week as the other tests but on separate days.  
 
 
The data will be analysed using appropriate statistical analysis and to determine the 
value of using the DIST test in post-gastric bypass subjects. 
The Mixed meal data will be analysed separately and compared against insulin 
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